Trial Profile
A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2022
Price :
$35
*
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Astrocytoma; Diffuse intrinsic pontine glioma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- Acronyms DIPG
- 21 Feb 2022 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.
- 21 Feb 2022 Planned primary completion date changed from 1 Jun 2025 to 1 Jun 2026.
- 21 Feb 2022 Planned initiation date changed from 1 Jun 2022 to 1 Jun 2024.